[Asia Economy Reporter Seo Sojeong] JW Bioscience, a subsidiary of JW Life Science, announced on the 14th that it has signed a non-exclusive technology licensing (general license) agreement for the patent of 'multiple biomarkers (CFB, CA19-9)' with Swedish diagnostic company Immunovia AB.
JW Bioscience's original patent relates to diagnostic technology that can detect pancreatic cancer early by simultaneously utilizing the biomarkers CFB and CA19-9. JW Bioscience holds the patent in Korea, the United States, 21 European countries, China, and Japan.
Under this agreement, Immunovia has secured global commercialization rights for CFB and CA19-9. Other details and the scale of the contract remain confidential by mutual agreement between the two companies.
JW Bioscience is expected to strengthen its favorable position in the global in vitro diagnostics market through the technology transfer agreement with Immunovia, which grants a non-exclusive license for the original patent.
JW Bioscience is currently developing an early pancreatic cancer diagnostic kit based on CFB and CA19-9 on its own. The company expects that once this kit is commercialized, it will be a groundbreaking alternative to unmet needs by enabling the detection of early-stage pancreatic cancer patients who can be completely cured by surgery with only a minimal amount of blood, thereby increasing survival rates through regular health checkups for early pancreatic cancer screening.
Ham Eun-kyung, CEO of JW Bioscience, said, "This agreement is significant in confirming JW's patent position in the global market and recognizing the excellence of JW's technology," adding, "Through collaboration with Immunovia, we can continuously secure clinical evidence for the biomarkers CFB and CA19-9, which will further strengthen our technological competitiveness."
Immunovia recently developed and exclusively sells the world's first pancreatic cancer early diagnosis LDT (Laboratory Developed Test) service in the United States.
Patrick Dahlen, CEO of Immunovia, said, "We are pleased to have signed this agreement to secure Immunovia's independent intellectual property rights," and added, "We will also consider development cooperation with JW Bioscience for the commercialization of pancreatic cancer early diagnosis services and kits."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
